Compugen
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Azrieli Center Building D 26 Harokmim St...Phone Number
+972 37658585Website
www.cgen.comRevenue
$42.7 MillionStock Symbol
CGENIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy.Explore more
Compugen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Compugen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Compugen, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Compugen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Compugen has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Compugen launches new products
Congratulate Masked Content for being promoted to Masked Content at Compugen
Funding: Get notified immidiatlly once Compugen has new funding data
Earning: See what the market has to say on Compugen recently announced quarterly report
Click to see if Compugen had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Compugen as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Compugen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Compugen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Compugen.
Compugen financials insights
Gather financial insights about Compugen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$51M
2021
Stock Offering
$20M
Compugen Tech Stack
A closer look at the technologies used by Compugen
See more technologies
Most Recent Scoops
Project
Compugen has announced that AstraZeneca presented updated data from the GEMINI-Hepatobiliary study at ASCO, showing rilvegostomig in combination with chemotherapy achieved 16.8 months of overall survival in first-line advanced biliary tract cancer, compared to less than 13 months in historical first-line trials for this indication.
Pharmaceuticals
Project
Compugen has announced that AstraZeneca has initiated a new Phase III trial, TROPiCS-04, evaluating rilvegostomig in combination with Dato-DXd in participants with high-risk muscle-invasive urothelial carcinoma in the adjuvant setting, bringing the total number of Phase III trials in the overall rilvegostomig program to twelve.
Clinical Operations
Project
Compugen has confirmed that the addition of the Phase III trial does not alter the existing agreement terms with AstraZeneca, and that Phase III readouts for rilvegostomig are guided by AstraZeneca for after 2027, with the possibility of earlier interim analyses.
Pharmaceuticals, Clinical Operations
Project
Compugen has indicated that no FDA meeting has been held to date regarding COM701, with regulatory engagement planned following the trial readout, and that the MAIA-ovarian trial design incorporates FDA guidelines including Project FrontRunner principles and a Bayesian trial design approach.
Compliance
Project
Medical Research, Clinical Operations
Compugen News & Media
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen Ltd. (CGEN) Q2 2026 Earnings Call August 3, 2026 8:30 AM EDTCompany ParticipantsLindsey TrickettEran Ophir - CEO, President & DirectorDavid...Compugen Reports Second Quarter 2026 Results
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the ESMO Gynaecological Cancers Congress 2026, reinforcing the biological and clinical rationale...Compugen to Participate in BTIG Biotechnology Conference 2026
HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the BTIG...Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Compugen
Sign Up For FreeTo access detailed company insights
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy.... Read More
